- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT05462873
Um estudo para investigar a segurança e tolerabilidade do QEQ278 intravenoso em pacientes com tumores sólidos avançados
Um estudo de Fase I/Ib, aberto, multicêntrico, de QEQ278 em pacientes com tumores sólidos avançados
To characterize safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of QEQ278 in adult patients with advanced/metastatic non-small cell lung cancer, esophageal squamous cell carcinoma, renal cell carcinoma, and human papilloma virus associated head and neck squamous cell carcinoma.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
This study is an open-label, phase I/Ib, multi-center study of QEQ278 as a single agent, consisting of a dose escalation part followed by a dose expansion part.
In the dose escalation part of the study, patients with non-small cell lung cancer (NSCLC), esophageal squamous cell carcinoma (ESCC), renal cell carcinoma (RCC), or human papilloma virus (HPV)-associated head and neck squamous cell carcinoma (HNSCC) will be treated with QEQ278 single agent until the maximum tolerated dose (MTD) is reached or a lower recommended dose (RD) is established.
The study may enter the dose expansion, after an MTD(s) and/or RD(s) is declared in the dose escalation.
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 1
Contactos e Locais
Locais de estudo
-
-
-
Essen, Alemanha, 45147
- Novartis Investigative Site
-
-
-
-
-
Brussels, Bélgica, 1200
- Novartis Investigative Site
-
-
-
-
-
Singapore, Cingapura, 168583
- Novartis Investigative Site
-
-
-
-
-
Barcelona, Espanha, 08035
- Novartis Investigative Site
-
-
-
-
California
-
Los Angeles, California, Estados Unidos, 90095
- University of California LA
-
-
Florida
-
Fort Myers, Florida, Estados Unidos, 33901
- Florida Cancer Specialists
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02114
- Massachusetts General Hospital
-
Boston, Massachusetts, Estados Unidos, 02114
- Massachusetts General Hospital Dept. of Mass General Hospital
-
-
-
-
-
Paris, França, 75231
- Novartis Investigative Site
-
-
-
-
MI
-
Milan, MI, Itália, 20133
- Novartis Investigative Site
-
-
-
-
Chiba
-
Kashiwa, Chiba, Japão, 2778577
- Novartis Investigative Site
-
-
-
-
-
Taipei, Taiwan, 10002
- Novartis Investigative Site
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Signed informed consent must be obtained prior to participation in the study.
- Adult men and women ≥ 18 years of age.
- Histologically confirmed and documented advanced malignancies (locally advanced malignancies, non-curable by surgery or radiotherapy and metastatic disease). Disease must be measurable, including presence of at least one measurable lesion, as determined by RECIST v1.1.
- In the opinion of the treating investigator, patients must have received, but are not benefitting from standard therapies, be intolerant or ineligible to receive such therapy, or have no standard therapy option for the respective disease types (diseases listed below), as well as any other therapies deemed to be standard by local/institutional standard.
- Non-small cell lung cancer
- Esophageal squamous cell carcinoma
- Renal cell carcinoma
- HPV-associated head and neck squamous cell carcinoma
- Must have a site of disease amenable to biopsy and be a candidate for tumor biopsy according to the treating institution's guidelines. The patient must be willing to undergo a new tumor biopsy at screening and during treatment.
Exclusion Criteria:
- Active previously documented or suspected autoimmune disease. Patients with vitiligo, type I diabetes, residual hypothyroidism only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur should not be excluded. Patients previously exposed to anti-PD-1/PD-L1 treatment who are adequately treated for skin rash or with replacement therapy for endocrinopathies should not be excluded.
- Patients with a history of or current interstitial lung disease or pneumonitis ≥ Grade 2.
- Patients who discontinued prior anti-PD-1 therapy due to an anti-PD-1-related toxicity
- Clinically significant cardiac disease or risk factors at screening
- Insufficient bone marrow function at screening:
- Infections:
- Known history of testing positive for Human Immunodeficiency Virus infection.
- Active Hepatitis B and / or Hepatitis C.
- Active, documented COVID-19 infection
- Known history of tuberculosis
- Any serious uncontrolled infection (acute or chronic).
- Systemic chronic steroid therapy (>10 mg/day prednisone or equivalent) or any immunosuppressive therapy, other than replacement-dose steroids in the setting of adrenal insufficiency, within 7 days of the first dose of study treatment. Topical, inhaled, and ophthalmic steroids are allowed.
Other protocol-defined inclusion/exclusion criteria may apply.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Part 1: Dose escalation
Dose escalation with QEQ278 single agent |
Intravenous dosing of QEQ278 |
|
Experimental: Part 2: Dose expansion
Dose expansion with QEQ278 single agent |
Intravenous dosing of QEQ278 |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Incidence and nature of Dose Limiting Toxicities (DLTs) during the DLT evaluation period for single agent QEQ278
Prazo: 28 days
|
A DLT is defined as an adverse event or abnormal laboratory value assessed as unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurs within the DLT evaluation period and meets the criteria defined in the study protocol. |
28 days
|
|
Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)
Prazo: Up to 31 months
|
Incidence and severity of adverse events (AEs) and serious adverse events (SAEs), including changes in laboratory values, vital signs, and electrocardiograms (ECGs) qualifying and reported as AEs. |
Up to 31 months
|
|
Frequency of dose interruptions, reductions
Prazo: Up to 30 months
|
Number of dose interruptions of QEQ278 and number of dose reductions of QEQ278 |
Up to 30 months
|
|
Dose intensity
Prazo: Up to 30 months
|
Dose intensity of QEQ278 is defined as the ratio of actual cumulative dose received and actual duration of exposure. |
Up to 30 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Overall response rate (ORR) per RECIST v1.1
Prazo: Up to 30 months
|
ORR is defined as the proportion of patients with a confirmed BOR of complete response (CR) or partial response (PR) by local investigator review as per RECIST v1.1. |
Up to 30 months
|
|
Disease control rate (DCR) per RECIST v1.1
Prazo: Up to 30 months
|
DCR is defined as the proportion of patients with a confirmed best overall response (BOR) of CR or PR or stable disease (SD) by local investigator review as per RECIST v1.1. |
Up to 30 months
|
|
Duration of Response (DOR) per RECIST v1.1
Prazo: Up to 30 months
|
DOR is defined as the time form the date of the first documented response (CR or PR) to the date of the first documented progression by local investigator review as per RECIST v1.1 or death due to underlying cancer. |
Up to 30 months
|
|
Progression-free survival (PFS) per RECIST v 1.1
Prazo: Up to 30 months
|
PFS is defined as the time from the date of start of treatment to the date of the first documented progression by local investigator review as per RECIST v1.1, or death due to any cause. |
Up to 30 months
|
|
Peak serum concentration (Cmax) of QEQ278
Prazo: During first 168 days of treatment
|
The maximum (peak) serum drug concentration after single dose administration |
During first 168 days of treatment
|
|
Area under the concentration time curve (AUC) last of QEQ278
Prazo: During first 168 days of treatment
|
The AUC from time zero to the last measurable concentration sampling time |
During first 168 days of treatment
|
|
Area under the concentration time curve (AUC) infinity of QEQ278
Prazo: During first 168 days of treatment
|
The AUC from time zero to infinity |
During first 168 days of treatment
|
|
Time to reach peak serum concentration (Tmax) of QEQ278
Prazo: During first 168 days of treatment
|
The time to reach maximum (peak) serum drug concentration after single dose administration |
During first 168 days of treatment
|
|
Elimination half-life (T1/2) of QEQ278
Prazo: During first 168 days of treatment
|
The elimination half-life associated with the terminal slope of a semi logarithmic concentration-time curve |
During first 168 days of treatment
|
|
Total body clearance (CL) of QEQ278
Prazo: During first 168 days of treatment
|
The total body clearance of drug from the serum |
During first 168 days of treatment
|
|
Volume of distribution (Vz) of QEQ278
Prazo: During first 168 days of treatment
|
The apparent volume of distribution during terminal phase |
During first 168 days of treatment
|
|
Incidence of anti-drug antibody (ADA)
Prazo: Day 1 and 15
|
Immunogenicity of QEQ278 |
Day 1 and 15
|
Colaboradores e Investigadores
Patrocinador
Publicações e links úteis
Links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças urogenitais
- Neoplasias urogenitais
- Neoplasias por local
- Neoplasias
- Doenças Urogenitais Masculinas
- Doenças renais
- Doenças Urológicas
- Doenças Urogenitais Femininas
- Doenças urogenitais femininas e complicações na gravidez
- Doenças Respiratórias
- Neoplasias por Tipo Histológico
- Neoplasias gastrointestinais
- Neoplasias do Aparelho Digestivo
- Doenças do aparelho digestivo
- Doenças Gastrointestinais
- Doenças pulmonares
- Neoplasias de Cabeça e Pescoço
- Neoplasias Glandulares e Epiteliais
- Adenocarcinoma
- Neoplasias do Trato Respiratório
- Neoplasias Torácicas
- Doenças Esofágicas
- Neoplasias Pulmonares
- Neoplasias Urológicas
- Carcinoma
- Neoplasias de Células Escamosas
- Neoplasias Renais
- Carcinoma Broncogênico
- Neoplasias Brônquicas
- Carcinoma de Células Escamosas
- Neoplasias Esofágicas
- Carcinoma Espinocelular de Cabeça e Pescoço
- Carcinoma Espinocelular de Esôfago
- Carcinoma de Células Renais
- Carcinoma pulmonar de células não pequenas
Outros números de identificação do estudo
- CQEQ278A12101
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .